Radius common stock is traded on the NASDAQ Global Market under the ticker symbol "RDUS."

750469 207

950 Winter St
Waltham, MA 02451

Radius does not offer a direct stock purchase plan. Shares of the Company should be purchased through a broker.

Radius does not currently pay a dividend.

Computershare
Investor Center Website
Shareholder Online Inquiries
Email

Telephone inquiries
1-877-373-6374 (US, Canada, Puerto Rico)
1-781-575-3100 (non-US)

Written requests
Computershare
P.O. Box 505000
Louisville, KY 40233-5000

By overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville KY 40202

To replace lost certificates, contact the transfer agent at:

Computershare
Investor Center Website
Shareholder Online Inquiries
Email

Telephone inquiries
1-877-373-6374 (US, Canada, Puerto Rico)
1-781-575-3100 (non-US)

Written requests
Computershare
P.O. Box 505000
Louisville, KY 40233-5000

By overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville KY 40202

To notify of a change in address, contact the transfer agent at:

Computershare
Investor Center Website
Shareholder Online Inquiries
Email

Telephone inquiries
1-877-373-6374 (US, Canada, Puerto Rico)
1-781-575-3100 (non-US)

Written requests
Computershare
P.O. Box 505000
Louisville, KY 40233-5000

By overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville KY 40202

Radius’ fiscal year is based on the calendar year.

First Quarter ends 3/31, Second Quarter ends 6/30, Third Quarter ends 9/30 and Fourth Quarter ends 12/31.

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology.

Radius' lead product, TYMLOS® (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer.

Please submit your question using the form below.

Contact Form
* Indicates required field
http://apps.shareholder.com/captcha/captcha.aspx?verifyid=2071880435&CompanyID=AMDA-1D3H6P&t=.jpg